MedTrace Logo

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

NCT00545142 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2010-06-25

No results posted yet for this study

Summary

To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.

Conditions

Interventions

DRUG

Abilify(Aripiprazole)

co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder

DRUG

Depakote(Divalproate)

co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Won-Myong Bahk, MD · St Mary's Hospital, London

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545142 on ClinicalTrials.gov